Host determinants in HIV infection and disease part 2: Genetic factors and implications for antiretroviral therapeutics

Annals of Internal Medicine

Volumn 134, Issue 10, 2001, Pages 978-996

  Hogan, Christine M ^a   Hammer, Scott M ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; ANTIBODY; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DNA VACCINE; GLYCOPROTEIN GP 41; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; OKT 3; RANTES; RECOMBINANT INTERLEUKIN 2; STROMAL CELL DERIVED FACTOR 1; T 22; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS RNA;

CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESISTANCE; GENE FREQUENCY; GENE MUTATION; GENE THERAPY; HELPER CELL; HETEROZYGOSITY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS REPLICATION;

EID: 0035873546     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-10-200105150-00012     Document Type: Review

References (257)

1. 8+ T cells. Science. 1995;270:1811-5. [PMID: 8525373]
2. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-7. [PMID: 8629022]
3. 4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667-73. [PMID: 8649512]
4. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955-8. [PMID: 8658171]
5. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996; 381:661-6. [PMID: 8649511]
6. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135-48. [PMID: 8674119]
7. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 1996;85:1149-58. [PMID: 8674120]
8. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35:3362-7. [PMID: 8977299]
9. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 1996;273:1856-62. [PMID: 8791590]
10. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367-77. [PMID: 8756719]
11. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240-3. [PMID: 8898752]
12. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med. 1997-3:23-36. [PMID: 9132277]
13. Michael NL, Nelson JA, KewalRamani VN, Chang G, O'Brien SJ, Mascola JR, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol. 1998;72:6040-7. [PMID: 9621067]
14. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-5. [PMID: 8751444]
15. Hoffman TL, MacGregor RR, Burger H, Mick R, Doms RW, Collman RG. CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J Infect Dis. 1997;176:1093-6. [PMID: 9333175]
16. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277:959-65. [PMID: 9252328]
17. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 1998;282:1907-11. [PMID: 9836644]
18. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med. 1997;127:882-90. [PMID: 9382366]
19. Meyer L, Magierowska M, Hubert JB, Theodorou I, van Rij R, Prins M, et al. CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS [Letter]. AIDS. 1999;13:624-6. [PMID: 10203391]
20. Ioannidis JP, O'Brien TR, Rosenberg PS, Contopoulos-loannidis DG, Goedert JJ. Genetic effects on HIV disease progression [Letter]. Nat Med. 1998; 4:536. [PMID: 9585207]
21. 4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1. J Infect Dis. 2000;181:927-32. [PMID: 10720514]
22. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, Rowland-Jones SL CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research [Letter]. Lancet. 1998;351:1632-3. [PMID: 9620723]
23. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 1998;4:350-3. [PMID: 9500612]
24. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998;4:786-93. [PMID: 9662369]
25. Rizzardi GP, Morawetz RA, Vicenzi E, Ghezzi S, Poli G, Lazzarin A, et al. CCR2 polymorphism and HIV disease. Swiss HIV Cohort [Lettet]. Nat Med. 1998;4:252-3. [PMID: 9500580]
26. Hendel H, Hénon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, et al. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquit Immune Defic Syndr Hum Retrovirol. 1998;19: 381-6. [PMID: 9833747]
27. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med. 1997;3:1160-2. [PMID: 9334732]
28. Eugen-Olsen J, Iversen AK, Benfield TL, Koppelhus U, Garred P. Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18: 110-6. [PMID: 9637575]
29. + mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J Infect Dis, 1999;179:825-31. [PMID: 10068577]
30. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, et al. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol. 1998;72:7450-8. [PMID: 9696841]
31. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-70. [PMID: 9742978]
32. Kostrikis L, Neumann A, Thomson B, Korber BT, McHardy P, Karanicolas R, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol. 1999;73:10264-71. [PMID: 10559343]
33. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829-33. [PMID: 8752280]
34. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996;382:833-5. [PMID: 8752281]
35. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-93. [PMID: 9430590]
36. van Rij R, Broersen S, Goudsmit J, Coutinho R, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS. 1998;12:F85-90. [PMID: 9662191]
37. Lathey J, Tierney C, Chang S, D'Aquila R, Hammer S, Katzenstein D. Homozygous mutations in 3′A SDF-1 are associated with more rapid disease progression. ACTG 175 Genotype Team [Abstract]. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 853.
38. + T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis. 2000; 182:311-5. [PMID: 10882614]
39. Balotta C, Bagnarelli P, Corvasce S, Mazzucchelli R, Colombo MC, Papagno L, et al. Identification of two distinct subsets of long-term nonprogressors with divergent viral activity by stromal-derived factor 1 chemokine gene polymorphism analysis. J Infect Dis. 1999;180:285-9. [PMID: 10395841]
40. Vicenzi E, Biswas P, Mengozzi M, Poli G. Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol. 1997; 62:34-40. [PMID: 9225990]
41. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238:800-2. [PMID: 3313729]
42. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A. 1989;86:5974-8. [PMID: 2762307]
43. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A. 1989;86:233640. [PMID: 2494664]
44. + T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci U S A. 1996;93:14076-81. [PMID: 8943063]
45. Wahl SM, Greenwell-Wild T, Peng G, Hale-Donze H, Orenstein JM. Co-infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages. J Infect Dis. 1999;179(Suppl 3):S457-60. [PMID: 10099119]
46. Goletti D, Weissman D, Jackson R, Graham N, Vlahov D, Klein R, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996;157:1271-8. [PMID: 8757635]
47. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182:1727-37. [PMID: 7500017]
48. Stanley S, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-30. [PMID: 8606717]
49. Kroon FP, Beersma MF, Kroes AC, Groeneveld PH, van Dissel JT. Vaccination and HIV-1 replication during highly active antiretroviral therapy [Letter]. AIDS. 1999;13:135-6. [PMID: 10207556]
50. + T-cell-derived soluble factor(s), but not β-chemokines RANTES, MIP-1 α, and MIP-1 β, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci U S A. 1996;93:15341-5. [PMID: 8986813]
51. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986; 234:1563-6. [PMID: 2431484]
52. (+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A. 1999;96:1030-5. [PMID: 9927688]
53. + cells involves a noncytotoxic mechanism. J Virol. 1991;65:5921-7. [PMID: 1920621]
54. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol. 1997;71:3120-8. [PMID: 9060675]
55. Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405-11. [PMID: 8597949]
56. Keet IP, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, et al. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis. 1999;180:299-309. [PMID: 10395843]
57. Tomiyama H, Miwa K, Shiga H, Moore YI, Oka S, Iwamoto A, et al. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J Immunol. 1997;158:5026-34. [PMID: 9144523]
58. Jeannet M, Sztajzel R, Carpentier N, Hirschel B, Tiercy JM. HLA antigens are risk factors for development of AIDS. J Acquit Immune Defic Syndr. 1989; 2:28-32. [PMID: 2783969]
59. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr. 1992;5:37-45. [PMID: 1738086]
60. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, Karita E, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 1999;15:317-24. [PMID: 10082114]
61. Klein MR, van der Burg SH, Hovenkamp E, Holwerda AM, Drijfhout JW, Melief CJ, et al. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol. 1998;79(Pt 9):2191-201. [PMID: 9747728]
62. Goulder PJ, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B, et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressons in HIV type 1 infection. AIDS Res Hum Retroviruses. 1996;12:1691-8. [PMID: 8959245]
63. Migueles SA, Sabbaghian MS, Shupert W, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A. 2000;97:2709-14. [PMID: 10694578]
64. Luster AD, Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-45. [PMID: 9459648]
65. Rizzuto CD, Wyatt R, Hernández-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 1998;280:1949-53. [PMID: 9632396]
66. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998;280:1884-8. [PMID: 9632381]
67. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-59. [PMID: 9641677]
68. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996;384:179-83. [PMID: 8906795]
69. Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1 [Letter]. Nature. 1998;391:240. [PMID: 9440686]
70. Simmons G, Wilkinson D, Reeves JD, Dittmat MT, Beddows S, Weber J, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol. 1996;70:8355-60. [PMID: 8970955]
71. (+) T cells: role of signal transduction. Proc Natl Acad Sci U S A. 1998;95:11880-5. [PMID: 9751759]
72. Simmons G, Clapham P, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 1997;276:276-9. [PMID: 9092481]
73. Arenzana-Seisdedos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B, et al. HIV blocked by chemokine antagonist [Letter]. Nature. 1996; 383:400. [PMID: 8837769]
74. Ylisastigui L, Vizzavona J, Drakopoulou E, Paindavoine P, Calvo CF, Parmentier M, et al. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages. AIDS. 1998;12:977-84. [PMID: 9662193]
75. Proudfoot A, Power C, Hoogewerf A, Montjovent MO, Borlat F, Offord RE, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem. 1996;271: 2599-603. [PMID: 8576227]
76. Gong JH, Uguccioni M, Dewald B, Baggiolini M, Clark-Lewis I. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem. 1996; 271:10521-7. [PMID: 8631850]
77. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol. 1999;73:4145-55. [PMID: 10196311]
78. Wu L, Paxton W, Kassam N, Ruffing N, Rottman JB, Sullivan N, et al. CCR5 levels and expression pattern correlate with infectability by macrophagetropic HIV-1, in vitro. J Exp Med. 1997;185:1681-91. [PMID: 9151905]
79. Trkola A, Ketas TJ, Nagashima K, Zhao L, Cilliers T, Morris L, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO140. J Virol. 2001;75:579-88. [PMID 11134270]
80. Baroudy B. A small molecule antagonist of CCR5 that effectively inhibits HIV-1 potential as a novel antiretroviral agent [Abstract]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. S17.
81. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol. 1999;73:3544-50. [PMID: 10196243]
82. Rusconi S, LaSeta Catamancio S, Citterio P, Bulgheroni E, Croce F, Herrmann S, et al. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infections: in vitro studies of mixed virus infection. J Virol. 2000;74:9328-32. [PMID: 10982382]
83. Rusconi S, Merrill D, LaSeta Catamancio S, Citterio P, Bulgheroni E, Croce F, et al. In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs. Antivir Ther. 2000;5:199-204. [PMID: 11075940]
84. Donzella GA, Schols D, Un SW, Esté JA, Nagashima K, Maddon PJ, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4:72-7. [PMID: 9427609]
85. Schols D, Esté JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 1997;35:147-56. [PMID: 9298754]
86. Schols D, Strayf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med. 1997;186:1383-8. [PMID: 9334378]
87. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med. 1997;186:1389-93. [PMID: 9334379]
88. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med. 1997;186:1395-400. [PMID: 9334380]
89. Zou YR, Kottmann AH, Kutoda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595-9. [PMID: 9634238]
90. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591-4. [PMID: 9634237]
91. Tremblay C, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000;25:99-102. [PMID: 11103038]
92. Hoffman TL, Doms RW. Chemokines and coreceptors in HIV/SIV-host interactions. AJDS. 1998; 12(Suppl A):S17-26. [PMID: 9632980]
93. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalizacion of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. 1997; 186:139-46. [PMID: 9207008]
94. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter N, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med. 1996;2:412-7. [PMID: 8597950]
95. (+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med. 1997;186:455-60. [PMID: 9236198]
96. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis. 1998; 177:331-6. [PMID: 9466518]
97. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Blé C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med. 1997;3:1250-7. [PMID: 9359700]
98. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr. Serum chemokine levels in patients with non-progressing HIV infection. AIDS. 1996; 10:F29-33. [PMID: 8853724]
99. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication [Letter], Nature. 1996;382:767. [PMID: 8752270]
100. Schmidtmayerova H, Nottet HS, Nuovo G, Raabe T, Flanagan CR, Dubrovsky L, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A. 1996;93:700-4. [PMID: 8570619]
101. Canque B, Rosenzwajg M, Gey A, Tartour E, Fridman WH, Gluckman JC. Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood. 1996;87:2011-9. [PMID: 8634452]
102. Li Q, Zupancic M, Zhang ZQ, Wong JK, Polis M, Feinberg M, et al. The levels of RANTES expression and HFV-1 replication in the lymphoid tissues of HIV-1-infected acute and chronic patients [Abstract], In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 393.
103. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo R, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science. 1997; 278:695-8. [PMID: 9381181]
104. Lee B, Rucker J, Doms RW, Tsang M, Hu X, Dietz M, et al. B-chemokine MDC and HIV-1 infection. Science (Technical Comments). 1998;281:487. Available at www.sciencemag.org/cgi/content/full/281/5376/487a. Accessed 30 December 1999.
105. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, et al. Homozygous Δ 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS. 1997;11:F67-71. [PMID: 9256936]
106. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele [Letter]. Nat Med. 1997;3:252-3. [PMID: 9055842]
107. O'Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael N, et al. HIV-1 infection in a man homozygous for CCR5 delta 32 [Letter]. Lancet. 1997;349:1219. [PMID: 9130945]
108. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-I infection in an individual homozygous for CCR5 delta 32. Seroco Study Group [Letter]. Lancet. 1997;349:1219-20. [PMID: 9130946]
109. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40. [PMID: 9055854]
110. Schønning K, Joost M, Gram G, Machuca R, Nielsen C, Nielsen J, et al. Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:195-202. [PMID: 9665495]
111. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet. 1997; 61:1261-7. [PMID: 9399903]
112. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Métais P, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet. 1998;351:14-8. [PMID: 9433423]
113. Garred P. Chemokine-receptor polymorphisms: clarity or confusion for HIV-1 prognosis? Lancet. 1998;351:2-3. [PMID: 9433416]
114. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem. 1997;272:30662-71. [PMID: 9388201]
115. + individuals with a structural variant of the chemokine receptor CX3CR1. Science. 2000;287:2274-7. [PMID: 10731151]
116. McDermott D, Beecroft MJ, Kleeberger C, Al-Sharif F, Ollier W, Zimmerman P, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progession in the Multicenter AIDS Cohort Study. AIDS. 2000;14:2671-8. [PMID: 11125885]
117. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS. 2000;14:821-6. [PMID: 10839590]
118. Guerin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, et al. CCR5-delta 32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2000;14:2788-90. [PMID: 11125899]
119. Workman C, Whittaker W, Forrester J, Dyer W, Sullivan J. Association of the CCR5del32 mutation with improved response to antiretroviral therapy commenced in primary HIV infection [Abstract]. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 570.
120. Aggarwal BB, Puri RK, eds. Human Cytokines: Their Role in Disease and Therapy. Cambridge, MA: Blackwell Scientific; 1995.
121. Baier M, Werner A, Bannert N, Metzner K, Kurth R, HIV suppression by interleukin-16 [Letter]. Nature. 1995;378:563. [PMID: 8524386]
122. Kinter AL, Poli G, Fox L, Hardy E, Fauci A. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol. 1995;154:2448-59. [PMID: 7868911]
123. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, et al. Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci U S A. 1998;95:8886-91. [PMID: 9671774]
124. Weissman D, Poli G, Fauci AS. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:442-9. [PMID: 7627621]
125. Poli G, Kinter AL, Justement JS, Bressler P, Kehrl JH, Fauci AS. Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med. 1991;173:589-97. [PMID: 1705278]
126. Weissman D, Poli G, Fauci AS. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and incerleukin 6 induction of virus. AIDS Res Hum Retroviruses. 1994; 10: 1199-206. [PMID: 7848677]
127. Claydon EJ, Bennett J, Gor D, Forster SM. Transient elevation of serum HIV antigen levels associated with intercurrent infection [Letter], AIDS. 1991;5: 113-4. [PMID: 1905552]
128. Perriëns JH, Mukadi Y, Nunn P. Tuberculosis and HIV infection: implications for Africa. AIDS. 1991;5(Suppl 1):S127-33. [PMID: 1669909]
129. Ho DD. HIV-1 viraemia and influenza [Letter]. Lancet. 1992;339:1549. [PMID: 1351231]
130. Janoff EN, Tasker SA, Stevenson M, Rubins JB, O'Brien J, Utz G, et al. Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. AIDS Res Hum Retroviruses. 1999;15:837-45. [PMID: 10381172]
131. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today. 1995;16:187-91. [PMID: 7734046]
132. Wolday D, Maayan S, Mariam ZG, Britton S, Landay A, Bentwich Z. Eradication of helminthic infection decreases HIV plasma viral load in dually infected people [Abstract]. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 157.
133. + T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation. J Immunol. 1996;156:4476-83. [PMID: 8666823]
134. + T cells. Immunol Today. 1996; 17:217-24. [PMID: 8991383]
135. Mackewicz CE, Yang LC, Lifson JD, Levy JA. Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet. 1994;344:1671-3. [PMID: 7996961]
136. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest. 1991;87: 1462-6. [PMID: 1707063]
137. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol. 1993;69:106-16. [PMID: 8403538]
138. Barker E, Mackewicz CE, Reyes-Terän G, Sato A, Stranford SA, Fujimura SH, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood. 1998;92:3105-14. [PMID: 9787145]
139. + T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses. 1997; 13:685-93. [PMID: 9168237]
140. + T lymphocytes from exposed uninfected individuals [Abstract]. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 159.
141. + T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. AIDS Res Hum Retroviruses. 1997;13:79-85. [PMID: 8989430]
142. Itescu S, Rose S, Dwyer E, Winchester R. Certain HLA-DR5 and -DR6 major histocompatibility complex class II alleles are associated with a CD8 lymphocytic host response to human immunodeficiency virus type 1 characterized by low lymphocyte viral strain heterogeneity and slow disease progression. Proc Natl Acad Sci U S A. 1994;91:11472-6. [PMID: 7972086]
143. Kroner BL, Goedert JJ, Blattner WA, Wilson SE, Carrington MN, Mann DL. Concordance of human leukocyte antigen haplotype-sharing, CD4 decline and AIDS in hemophilic siblings. Multicenter Hemophilia Cohort and Hemophilia Growth and Development Studies. AIDS. 1995;9:275-80. [PMID: 7755916]
144. Plummer FA, Ball TB, Kimani J, Fowke KR. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop? Immunol Lett. 1999;66:27-34. [PMID: 10203031]
145. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest. 1998;102:1758-65. [PMID: 9802890]
146. Kaul R, Trabattoni D, Bwayo JJ, Arienti D, Zagliani A, Mwangi FM, et al. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS. 1999;13:23-9. [PMID: 10207541]
147. Hill AV. HIV and HLA: confusion or complexity? Nat Med. 1996;2:395-6. [PMID: 8597943]
148. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science. 1999;283:1748-52, [PMID: 10073943]
149. McNeil AJ, Yap PL, Gore SM, Bretde RP, McColl M, Wyld R, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM. 1996;89:177-85. [PMID: 8731561]
150. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997;3:212-7. [PMID: 9018241]
151. Goldfeld AE, Flores-Villanueva P, Vittinghoff E, Buchbinder S, Delgado JC, Leung JY, et al, HLA-Bω4 homozygosity is associated with profound suppression of HIV-1 viremia and long-term non-progression to AIDS [Abstract]. In: 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Late Breaker Abstract no. 4.
152. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162:6942-6. [PMID: 10352317]
153. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. [PMID: 9516219]
154. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33. [PMID: 9287227]
155. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-91. [PMID: 9144290]
156. Ho DD. Time to hit HIV, early and hard [Editorial]. N Engl J Med. 1995;333:450-1. [PMID: 7616996]
157. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Idencification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-300. [PMID: 9360927]
158. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-5. [PMID: 9360926]
159. (+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869-73. [PMID: 9671771]
160. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-13. [PMID: 10341272]
161. + T cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy. Nat Med. 1999;5:512-7. [PMID: 10229227]
162. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med. 2000;6:82-5. [PMID: 10613829]
163. Furtado MR, Callaway DS, Phair JP, Kunstman K, Stanton J, Macken C, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-22. [PMID: 10341273]
164. Martinez-Picado J, DePasquale M, Kartsonis N, Hanna G, Wong J, Finzi D, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Nad Acad Sci U S A. 2000;97:10948-53. [PMID: 11005867]
165. Saag MS, Kilby JM. HIV-1 and HAART: a time to cure, a time to kill. Nat Med. 1999;5:609-11. [PMID: 10371490]
166. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651-5. [PMID: 10371503]
167. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS. Re-emergence of HIV after stopping therapy. Nature. 1999;401:874-5. [PMID: 10553903]
168. Stellbrink HJ, Van Lunzen J, Westby M, O'Sullivan E, Cammack N, Adam A, et al. Influence of interleukin-2 (IL-2) on productive and latent HIV infection and on viral rebound [Abstract]. In: 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 240.
169. Ho DD, Toward HIV eradication or remission: the tasks ahead. Science. 1998;280:1866-7. [PMID: 9669944]
170. Cohen J. Exploring how to get at - and eradicate - hidden HIV. Science. 1998;279:1854-5. [PMID: 9537902]
171. Fraser C, Ferguson NM, Ghani AC, Prins JM, Lange J, Goudsmit J, et al. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS, 2000;14:659-69. [PMID: 10807189].
172. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens P, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 1999;13:2405-10. [PMID: 10597782]
173. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol. 1999;73:6721-8. [PMID: 10400770]
174. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-6. [PMID: 9516110]
175. (+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol. 1999;73:7108-16. [PMID: 10438796]
176. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression, Nat Med. 1999; 5:518-25. [PMID: 10229228]
177. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999;73:797-800. [PMID: 9847391]
178. Musey LK, Krieger JN, Hughes JP, Schacker TW, Corey L, McElrath MJ. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis. 1999;180:278-84. [PMID: 10395840]
179. Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retroviruses. 1998;14(Suppl 20):S143-7. [PMID: 9672231]
180. + T cell responses associated with control of viremia. Science. 1997;278:1447-50. [PMID: 9367954]
181. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowia M, et al. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000;181:1249-63. [PMID: 10762561]
182. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy [Letter]. N Engl J Med. 1999;340:1683-4. [PMID: 10348681]
183. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest, 1999;104:R13-8. [PMID: 10491418]
184. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-6. [PMID: 11029005]
185. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000;182:766-75. [PMID: 10950770]
186. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat M, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000;14:397-403.
187. Garcia F, Plana M, Ortiz GM, Soriano A, Vidal C, Cruceta A, et al. Structured cyclic antiretroviral therapy interruption (STI) in chronic infection may induce immune responses against HIV-1 antigens associated with spontaneous drop in viral load [Abstract]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Late Breaker Abstract no. 11.
188. Fagard C, Lebraz M, Tortajada C, Garcia F, Bernasconi E, Battegay M, et al. SITT: a prospective trial of strategic treatment interruptions [Abstract]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 458.
189. Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV-1 infection [Letter]. Lancet. 2000; 355:287-8. [PMID: 10675080]
190. García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999;13:F79-86. [PMID: 10449278]
191. Neumann AU, Tubiana R, Calvez V, Robert C, Li TS, Agut H, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 1999;13: 677-83. [PMID: 10397562]
192. Lori F, Lewis M, Xu J, Varga G, Zinn D, Crabbs C, et al. Control of SIV rebound through structured treatment interruptions during eatly infection. Science. 2000;290:1591-3. [PMID: 11090360]
193. Decks S, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J, et al. Virologie and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-80. [PMID: 11172188]
194. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy, AIDS. 1999; 13:F123-7. [PMID: 10630517]
195. Miller V, Satin C, Hertogs K, Bloor S, Maronez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-67. [PMID: 11153667]
196. Dybul M, Yoder C, Belson M, Chun TW, Hallahan C, Justement JS, et al. A randomized controlled trial of intermittent versus continuous highly active antiretroviral therapy (HAART) [Abstract]. In: Extended Version of the Abstracts: Social Science, Rights, Politics, Commitment and Action. XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Bologna: Monduzzi Editore, International Proceedings Division; 2000. Abstract no. LbOr11.
197. Dybul M, Yoder C, Belson M, Hallahan C, Hertogs K, Larder B, et al. Short cycle intermittent HAART: a pilot study [Abstract]. In: Extended Version of the Abstracts: Social Science, Rights, Politics, Commitment and Action. XIII International AIDS Conference, Durban, South Africa, 9-14 July 2000. Bologna: Monduzzi Editore, International Proceedings Division; 2000. Abstract no. LbOr12.
198. Hoff R, McNanura J. Therapeutic vaccines for preventing AIDS: their use with HAART. Lancet. 1999;353:1723-4. [PMID: 10347978]
199. Pontesilli O, Guerra EC, Ammassari A, Tomino C, Carlesimo M, Antinori A, et al. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS. 1998;12:473-80. [PMID: 9543445]
200. Tsoukas CM, Raboud J, Bernard NF, Montaner JS, Gill MJ, Rachlis A, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency, AIDS Res Hum Retroviruses. 1998;14:483-90. [PMID: 9566550]
201. Ratto-Kim S, Sitz KV, Garner RP, Kim JH, Davis C, Aronson N, et al. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferate response. J Infect Dis. 1999;179:337-44. [PMID: 9878016]
202. Trauger RJ, Daigle AE, Giermakowska W, Moss RB, Jensen F, Carlo DJ. Safety and immunogenicity of agp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(Suppl 2):S74-82. [PMID: 7552517]
203. 6/L CD4 cell counts: a randomized controlled trial. JAMA. 2000;284:2193-202. [PMID: 11056590]
204. Sandström E, Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet. 1999;353:1735-42. [PMID: 10347985]
205. Churdboonchart V, Moss RB, Sirawaraporn W, Smutharaks B, Sutthent R, Jensen FC, et al. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS. 1998;12:1521-7. [PMID: 9727574]
206. Bratt G, Eriksson LE, Sandström E, Gilljam G, Hinkula J, Albert J, et al. Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment. Int J STD AIDS. 1999;10:514-21. [PMID: 10471100]
207. Moss RB, Wallace RB, Giermakowska WK, Webb E, Savary J, Chamberlin-Brandt C, et al. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. J Infect Dis. 1999;180:641-8. [PMID: 10438350]
208. Moss RB, Giermakowska WK, Savary JR, Theofan G, Daigle AE, Richieri S, et al. A primer on HIV type 1-specific immune function and REMUNE. AIDS Res Hum Retroviruses. 1998;14(Suppl 2):S167-75. [PMID: 9672235]
209. 251 infection of macaques. Mat Med. 2000;6:1140-6. [PMID: 11017146]
210. Jin X, Bauer D, Binley J, Chen D, Ramanathan M, Barsoum S, et al. Safety and immunogenicity study on vCP1452/gp160 vaccine in patients treated with HAART for over two years [Abstract]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 346.
211. Jin X, Ramanathan M, Barsoum S, Bauer D, Chen D, Hurley A, et al. Discontinuation of HAART after a course of therapeutic vaccination with ALVAC1452 and rgp160 may be associated with delayed viral rebound kinetics [Abstract]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Late Breaker Abstract no. 12.
212. + T-cell responses during potent antiretroviral drug therapy by stimulation with antigen-loaded dendritic cells [Abstract]. In: Program and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, 30 January-2 February 2000. Alexandria, VA: Foundation for Retrovirology and Human Health; 2000. Abstract no. 834.
213. Wilson CC, Olson WC, Tuting T, Rinaldo CR, Lotze MT, Storkus WJ. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol. 1999;162:3070-8. [PMID: 10072560]
214. Sodroski JG. HIV-1 entry inhibitors in the side pocket. Cell. 1999;99: 243-6. [PMID: 10555140]
215. Chan DC, Kim PS. HIV entry and its inhibition. Cell. 1998;93:681-4. [PMID: 9630213]
216. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-7. [PMID: 9809555]
217. Trkola A, Paxton WA, Monard SP, Hoxie JA, Siani MA, Thompson DA, et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol. 1998;72:396-404. [PMID: 9420238]
218. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol. 1999;73:684-94. [PMID: 9847374]
219. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-I. Nature. 1996;382:635-8. [PMID: 8757135]
220. Endres MJ, Jaffer S, Haggarty B, Turner JD, Doranz BJ, O'Brien PJ, et al. Targeting of HIV-and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science. 1997;278:1462-4. [PMID: 9367958]
221. Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 1997; 90:849-57. [PMID: 9298897]
222. Mebatsion T, Finke S, Weiland F, Conzelmann KK. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell. 1997;90:841-7. [PMID: 9298896]
223. Cairns JS, D'Souza MP. Chemokines and HIV-1 second receptors: the therapeutic connection. Nat Med. 1998;4:563-8. [PMID: 9585229]
224. Cammack N. Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target. Antivir Chem Chemother. 1999;10:53-62. [PMID: 10335399]
225. Rowland-Jones S. The role of chemokine receptors in HIV infection. Sex Transm Infect. 1999;75:148-51. [PMID: 10448390]
226. Proudfoot AE, Wells TN, Clapham PR. Chemokine receptors - future therapeutic targets for HIV? Biochem Pharmacol. 1999;57:451-63. [PMID: 9952309]
227. Roos MT, Lange JM, de Goede RE, Coutinho RA, Schellekens PT, Miedema F, et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis. 1992;165:427-32. [PMID: 1347054]
228. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1 [Letter]. J Infect Dis. 1997;175:231-2. [PMID: 8985228]
229. Cornelissen M, Mulder-Kampinga G, Veenstra J, Zoigdragcr F, Kuiken C, Hartman S, et al. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol. 1995;69: 1810-8. [PMID: 7853521]
230. Michael NL, Moore JP. HIV-1 entry inhibitors: evading the issue. Nat Med. 1999;5:740-2. [PMID: 10395316]
231. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today. 1996;17:21-4. [PMID: 8652046]
232. Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J Infect Dis. 1995;172:1175-83. [PMID: 7594651]
233. Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1997;13:1163-77. [PMID: 9310283]
234. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1996;173:340-8. [PMID: 8568294]
235. Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis. 1997;175:764-74. [PMID: 9086128]
236. Montefiori DC, Evans TG. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS RES Hum Retroviruses. 1999;15:689-98. [PMID: 10357464]
237. Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis. 1998;177:301-9. [PMID: 9466515]
238. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis. 1999;180: 290-8. [PMID: 10395842]
239. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis. 1998;177:1230-46. [PMID: 9593008]
240. Belshe RB, Gorse GJ, Mulligan M, Evans TG, Keefer MC, Excler JL, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS. 1998;12:2407-15. [PMID: 9875578]
241. Salmon-Céron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses. 1999;15:633-45. [PMID: 10331442]
242. Ourmanov I, Bilska M, Hirsch VM, Montefiori DC. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J Virol. 2000-.74-.2960-5. [PMID: 10684319]
243. Fomsgaard A. HIV-1 DNA vaccines. Immunol Lett. 1999;65:127-31. [PMID: 10065638]
244. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Nad Acad Sci USA. 1997;94: 1396-401. [PMID: 9037064]
245. Janssens W, Buvé A, Nkengasong JN. The puzzle of HIV-1 subtypes in Africa [Editorial]. AIDS. 1997;11:705-12. [PMID: 9143601]
246. Falk LA, Goldenthal KL, Esparza J, Aguado MT, Osmanov S, Ballou WR, et al. Recombinant bacillus Calmette-Guérin as a potential vector far preventive HIV type 1 vaccines. AIDS Res Hum Retroviruses. 2000;16:91-8. [PMID: 10659047]
247. Mestecky J, Jackson S. Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines. J Clin Immunol. 1994;14:259-72. [PMID: 7814455]
248. Lehner T, Wang Y, Ping L, Bergmeier L, Mitchell E, Cranage M, et al. The effect of route of immunization on mucosal immunity and protection. J Infect Dis. 1999;179(Suppl 3):S489-92. [PMID: 10099126]
249. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med. 1996;2: 767-75. [PMID: 8673922]
250. Schnell MJ, Foley H, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A. 2000;97:3544-9. [PMID: 10706640]
251. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:195-203. [PMID: 9390572]
252. Francis DP, Gregoty T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, et al. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses. 1998;14 Suppl 3:5325-31. [PMID: 9814961]
253. Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol. 2000;74:2502-9. [PMID: 10684264]
254. Egan MA, Charini WA, Kuroda MJ, Schmia JE, Racz P, Tenner-Racz K, et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol. 2000;74:7485-95. [PMID: 10906202]
255. Barouch D, Sanaa S, Schmitz J, Kuroda M, Fu T, Wagner W, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290:486-92.
256. Wagner R, Shao Y, Wolf H. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine. 1999;17: 1706-10. [PMID: 10194826]
257. Rousseau MC, Moreau J, Delmont J. Vaccination and HIV: a review of the literature. Vaccine. 1999;18:825-31. [PMID: 10580195]